about
The gap between guidelines and reality: Type 2 diabetes in a National Diabetes Register 1996-2003The true value of HbA1c as a predictor of diabetic complications: simulations of HbA1c variables.Predicting mortality in people with type 2 diabetes mellitus after major complications: a study using Swedish National Diabetes Register data.Health utilities of type 2 diabetes-related complications: a cross-sectional study in Sweden.Metabolic effects of Basal or premixed insulin treatment in 5077 insulin-naïve type 2 diabetes patients: registry-based observational study in clinical practice.Total costs of basal or premixed insulin treatment in 5077 insulin-naïve type 2 diabetes patients: register-based observational study in clinical practice.Adipocyte hypertrophy, inflammation and fibrosis characterize subcutaneous adipose tissue of healthy, non-obese subjects predisposed to type 2 diabetes.Cost-utility analysis of glucagon-like Peptide-1 agonists compared with dipeptidyl peptidase-4 inhibitors or neutral protamine hagedorn Basal insulin as add-on to metformin in type 2 diabetes in swedenCigarette smoking and diabetes.Adipocyte mitochondrial genes and the forkhead factor FOXC2 are decreased in type 2 diabetes patients and normalized in response to rosiglitazoneMetabolic predictors of impaired glucose tolerance and type 2 diabetes in a predisposed population--A prospective cohort study.Minor Contribution of Endogenous GLP-1 and GLP-2 to Postprandial Lipemia in Obese Men.Amelioration of insulin resistance by rosiglitazone is associated with increased adipose cell size in obese type 2 diabetic patients.Does the choice of EQ-5D tariff matter? A comparison of the Swedish EQ-5D-3L index score with UK, US, Germany and Denmark among type 2 diabetes patientsThe size of large adipose cells is a predictor of insulin resistance in first-degree relatives of type 2 diabetic patientsCephalic phase of insulin secretion in response to a meal is unrelated to family history of type 2 diabetesClinical Effects and Safety of Direct-Acting Insulin Analogs in Patients with Type 1 Diabetes: A Nation-Wide Observational Cohort Study.The role of chloramines in treatment of diabetic foot ulcers: an exploratory multicentre randomised controlled trial.Antihyperglycaemic treatment of type 2 diabetes: results from a national diabetes register.Estimated glucose disposal rate and long-term survival in type 2 diabetes after coronary artery bypass grafting.Glycemic Control in Type 1 Diabetes and Long-Term Risk of Cardiovascular Events or Death After Coronary Artery Bypass Grafting.Recent trends in life expectancy for people with type 1 diabetes in Sweden.LDL cholesterol is not a good marker of cardiovascular risk in Type 1 diabetes.Relationship between preoperative hemoglobin A1c levels and long-term mortality after coronary artery bypass grafting in patients with type 2 diabetes mellitus.Increased Urine IgM and IgG(2) Levels, Indicating Decreased Glomerular Size Selectivity, Are Not Affected by Dalteparin Therapy in Patients with Type 2 Diabetes.Effect of smoking reduction and cessation on cardiovascular risk factors.Thiazolidinediones increase the wingless-type MMTV integration site family (WNT) inhibitor Dickkopf-1 in adipocytes: a link with osteogenesis.Long-term mortality in patients with type 2 diabetes undergoing coronary angiography: the impact of glucose-lowering treatment.Variability of INR and its relationship with mortality, stroke, bleeding and hospitalisations in patients with atrial fibrillation.Severe hypoglycemia and mortality after cardiovascular events for type 1 diabetic patients in Sweden.Microalbuminuria and risk factors in type 1 and type 2 diabetic patients.The effect of alogliptin and pioglitazone combination therapy on various aspects of β-cell function in patients with recent-onset type 2 diabetes.The effect of insulin lispro on glycemic control in a large patient cohort.Optimization of basal insulin delivery in Type 1 diabetes: a retrospective study on the use of continuous subcutaneous insulin infusion and insulin glargine.LDL-cholesterol versus non-HDL-to-HDL-cholesterol ratio and risk for coronary heart disease in type 2 diabetes.Obesity and cardiovascular risk factors in type 2 diabetes: results from the Swedish National Diabetes Register.Effect of 3 Years of Treatment With Exenatide on Postprandial Glucagon Levels.The relationship between the exposure time of insulin glargine and risk of breast and prostate cancer: an observational study of the time-dependent effects of antidiabetic treatments in patients with diabetes.Pulse pressure strongly predicts cardiovascular disease risk in patients with type 2 diabetes from the Swedish National Diabetes Register (NDR).Impaired phosphorylation and insulin-stimulated translocation to the plasma membrane of protein kinase B/Akt in adipocytes from Type II diabetic subjects
P50
Q28192065-677D022B-5BFC-428F-816A-A2479B5E6050Q30485840-FDF94CA9-1850-4AE1-8179-307D91BAD18DQ30805323-8DACD958-05CC-4930-87EC-ECEAF8E7A306Q33742403-7E31223D-D077-432A-8BC9-965A71864CD1Q33785179-F303F325-0F2C-4557-B99C-C01A9DA1F702Q33801252-D2FD26D4-286A-4D46-9112-6E30750CF156Q34078663-4C0CA86C-DDA5-4AAD-868A-A979E5D638FBQ34726534-E73438B0-04AE-46C6-B4D1-ADCE5638B466Q35110926-4D5560AC-FB5D-493C-8EE7-FA074A06FB2EQ35591020-9F3C2104-976B-4981-8A2C-B188123A7EC2Q35789001-5E686396-E780-4635-BA35-3BE68F64948FQ35890612-8FC5ED87-085C-4EC5-861B-A315708CC08AQ35998787-E53E3C78-FB73-408E-B2A1-C4A2FA342AB4Q36067153-E06A568C-9632-42E4-BD16-8E231D685C04Q36277920-4F2E74F5-29E4-49FC-80D9-1E8EA493AB60Q36306198-BC56CFF4-B162-4209-9003-206343EF8EF3Q37239321-835F09F7-4D9F-4EDC-A891-D56D33AF5435Q38889426-80F0E89A-2E67-478F-8364-2117052490A2Q40213395-3ACA1D39-96B9-4508-8F1C-F0BBDC33CCB4Q40656834-EC372C28-57CD-4491-A64E-4790BD0E065EQ40676923-3A6BBA43-6154-415A-BF3F-9E243395C461Q40818308-BB8AE28E-58BD-4287-9B8E-3C1B4F84D22DQ41188538-7CA78B4A-5213-4453-A2BA-E363E8F817E3Q41302260-18E55BB9-ABD4-46AE-97CC-4E5E866264C1Q41566844-CEA9F4B6-7AF9-41A7-AA35-6168BA9F3D4FQ42656987-5FD5157C-09E2-4C48-B0DD-9392E5E1152DQ42831868-951BAA3C-6D83-4CE9-94A7-6B426147D63CQ44261864-C9191EB6-0D9E-4D83-A0B2-5A9FF45FBA41Q44698859-32E7D551-3C76-467F-AB22-86B65A0A1591Q45252459-03E711CB-02C7-4AA4-BAED-2F0A9D98E8EAQ45266786-BD720A07-AB00-496A-9196-09575A559F51Q46134952-B16F3775-619E-4FBD-BC8F-88AF636C6C79Q46170045-228B9362-8DD4-45E7-825A-40D1F07E9907Q46401183-166B4EF3-7DEA-411D-BCBC-8409878576E6Q46942263-70DE9294-77BC-4862-A276-043A9A5C3A24Q46942501-E2D26F17-F777-4409-8B9B-0013024A30FAQ48270788-FC771AD8-381F-4BCE-87F9-EB0CC486A978Q51392679-5D7F5817-C95E-40B0-A3A4-9ED90B26F0FAQ51610291-A2BB47A1-E95D-4889-8839-EDCB688119FCQ59466700-3CE9AB42-1987-4BB4-925D-63E7C4E4F10D
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Bjorn Eliasson
@ast
Bjorn Eliasson
@en
Bjorn Eliasson
@es
Bjorn Eliasson
@nl
type
label
Bjorn Eliasson
@ast
Bjorn Eliasson
@en
Bjorn Eliasson
@es
Bjorn Eliasson
@nl
prefLabel
Bjorn Eliasson
@ast
Bjorn Eliasson
@en
Bjorn Eliasson
@es
Bjorn Eliasson
@nl
P106
P31
P496
0000-0003-2569-4160